Diclofenac as a KMO Inhibitor

Running, not enrolling · Early Phase 1 · Has a placebo group

Conditions studied: Alcohol Use Disorder

In brief

This mechanistic, proof of concept laboratory study will test the pharmacological properties of diclofenac in individuals with AUD. Participants will complete two sessions in which they will receive a single dose of diclofenac (100 mg) or matched placebo in a randomized and double blind fashion. The primary aim is to assess whether this dose of diclofenac, vs. placebo, increases circulating levels of kynurenic acid. This finding would provide evidence that diclofenac (100 mg) inhibits the kynurenine 3-monooxygenase enzyme.

Key facts

Study ID
NCT06029296
Run by
University of Maryland, Baltimore
People needed
12
Starts
2024-07-31
Expected to finish
2026-08-01
Last updated by the study team
2026-03-27

Who can join

Age: 21 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.